Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2021-10-14 Regulatory Filings
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated October 14, 2021, announcing that Adocia's partner, Tonghua Dongbao, received authorization from the Chinese NMPA to commence Phase 3 clinical trials for BioChaperone® Lispro. It details the significance of this milestone, financial implications (milestone payment), market context, and provides extensive background on the drug and the companies involved. This content aligns perfectly with an Earnings Release (ER) or a general corporate update, but since it is a specific announcement of a major operational/clinical milestone rather than just summarizing quarterly financial results (ER) or providing a full management discussion (MDA), it fits best as a general corporate announcement. Given the options, it is a significant corporate update that doesn't fit the specific definitions of 10-K, AR, CT, or IR. It is not a simple announcement of a report publication (RPA). Since it details a major development in drug trials and partnership progress, it is best classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard corporate news, or potentially an Earnings Release (ER) if such milestones are typically bundled there, but ER usually focuses on financial performance periods. Given the focus on clinical trial progression and regulatory authorization, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for a significant, non-periodic corporate event announcement that isn't a specific financial report.
2021-10-14 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled as a "PRESS RELEASE" and its primary content is the announcement of the "Total number of outstanding shares as well as its voting rights as of September 30th, 2021," citing French regulatory requirements (Code de Commerce and AMF charter). This type of periodic disclosure regarding share capital structure and voting rights, especially when presented as a brief press release, aligns best with filings related to capital structure changes or major shareholding notifications. Since it specifically details the total number of shares and voting rights, it is a direct notification of the current capital structure. This fits the description of 'Share Issue/Capital Change' (SHA) or potentially 'Major Shareholding Notification' (MRQ) if the context implied a threshold crossing, but the core data is the total share count. Given the options, 'SHA' (Share Issue/Capital Change) is the most appropriate fit for a formal announcement detailing the total outstanding share count and voting rights, as this forms the basis of the capital structure. It is not a full financial report (10-K, IR) or an earnings release (ER).
2021-10-12 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 30 septembre 2021" (Information relative to the number of shares and voting rights as of September 30, 2021). It explicitly states it is published in accordance with French commercial code and AMF regulations (Autorité des Marchés Financiers) to report the total number of shares and voting rights as of a specific date. This type of mandatory disclosure regarding share capital structure and voting power is a specific regulatory filing, often related to major shareholding notifications or capital structure updates, but the core content is the official count of shares and voting rights. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit for notifications concerning changes in share ownership thresholds or capital structure reporting, although this specific report is a periodic update of the total count. Given the context of reporting share counts and voting rights based on regulatory requirements (L.233-8 II du Code de Commerce and article 223-16 du Règlement Général de l'AMF), it aligns best with notifications related to significant share movements or capital structure reporting. Since it is a formal, periodic regulatory disclosure about the capital base, and not a general announcement (RPA/RNS) or a management/board change, 'MRQ' (Major Shareholding Notification) is the most appropriate classification for this type of capital structure disclosure, even if it's a routine update rather than a threshold breach announcement.
2021-10-12 French
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its main subject is the announcement of the live broadcast of the company's Annual General Meeting ("assemblée générale annuelle" or AGM) scheduled for May 20, 2021. It details the logistics of the AGM, including participation rules, deadlines for written questions, and where documentation is available. Since the document is an announcement about the AGM logistics and materials, and not the presentation itself or the voting results, it aligns best with the category for AGM-related information. The code 'AGM-R' covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. Although it is an announcement, the content is directly about the AGM event and its associated materials, making AGM-R more specific than a general RPA or RNS.
2021-10-01 French
Rapport semestriel 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Rapport Semestriel 2021' (Half-Year Report 2021) for Adocia, covering the period ending June 30, 2021. It contains comprehensive financial statements, management discussion and analysis (MDA), and an audit report summary. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H2 2021
2021-09-30 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing that Adocia will deliver an oral presentation about its drug candidate M1Pram at the 57th Annual Meeting of the European Association for the Study of Diabetes (EASD). It details the date, time, session, and title of the presentation, and provides background information on the company and the conference. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing like a proxy statement or earnings release. It is an announcement related to investor/scientific communication, specifically about a presentation at a major industry meeting. This fits best under Investor Presentation (IP) as it details scientific/clinical data being presented to the investment community and peers, or potentially a Regulatory Filing (RNS) if it were purely administrative. Given the focus on presenting clinical trial data at a major scientific meeting, 'Investor Presentation' (IP) is the most appropriate category, as these announcements often precede or accompany the actual presentation materials shared with investors.
2021-09-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.